Insider Trading Alert - AKAM, NPSP And FNFG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 13, 2014, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $292.00 to $15,496,000.00.

Highlighted Stocks Traded by Insiders:

Akamai Technologies (AKAM) - FREE Research Report

Craig Pamela J., who is Director at Akamai Technologies, bought 1,640 shares at $61.22 on Nov. 13, 2014. Following this transaction, the Director owned 14,088 shares meaning that the stake was boosted by 13.17% with the 1,640-share transaction.

The shares most recently traded at $61.72, up $0.50, or 0.81% since the insider transaction. Historical insider transactions for Akamai Technologies go as follows:

  • 4-Week # shares bought: 9,500
  • 4-Week # shares sold: 31,131
  • 12-Week # shares bought: 9,500
  • 12-Week # shares sold: 31,131
  • 24-Week # shares bought: 9,500
  • 24-Week # shares sold: 33,513

The average volume for Akamai Technologies has been 1.6 million shares per day over the past 30 days. Akamai Technologies has a market cap of $10.8 billion and is part of the technology sector and internet industry. Shares are up 28.13% year-to-date as of the close of trading on Thursday.

Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing online content and business applications in the United States and internationally. The company has a P/E ratio of 34.7. Currently, there are 15 analysts who rate Akamai Technologies a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AKAM - FREE

TheStreet Quant Ratings rates Akamai Technologies as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Akamai Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NPS Pharmaceuticals (NPSP) - FREE Research Report

Selisker Rachel R, who is Director at NPS Pharmaceuticals, sold 15,188 shares at $29.50 on Nov. 13, 2014. Following this transaction, the Director owned 9,900 shares meaning that the stake was reduced by 60.54% with the 15,188-share transaction.

The shares most recently traded at $29.05, down $0.45, or 1.56% since the insider transaction. Historical insider transactions for NPS Pharmaceuticals go as follows:

  • 4-Week # shares sold: 40,635
  • 12-Week # shares sold: 40,635
  • 24-Week # shares sold: 40,635

The average volume for NPS Pharmaceuticals has been 2.1 million shares per day over the past 30 days. NPS Pharmaceuticals has a market cap of $3.1 billion and is part of the health care sector and drugs industry. Shares are down 1.91% year-to-date as of the close of trading on Thursday.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company has a P/E ratio of 1458.5. Currently, there are 7 analysts who rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NPSP - FREE

TheStreet Quant Ratings rates NPS Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full NPS Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

First Niagara Financial Group (FNFG) - FREE Research Report

Highsmith Carlton L, who is Director at First Niagara Financial Group, bought 15,000 shares at $7.53 on Nov. 13, 2014. Following this transaction, the Director owned 69,159 shares meaning that the stake was boosted by 27.7% with the 15,000-share transaction.

Saffire Joseph, who is Managing Director, Head of Com at First Niagara Financial Group, bought 10,000 shares at $7.77 on Nov. 13, 2014. Following this transaction, the Managing Director, Head of Com owned 62,836 shares meaning that the stake was boosted by 18.93% with the 10,000-share transaction.

The shares most recently traded at $8.04, up $0.27, or 3.36% since the insider transaction. Historical insider transactions for First Niagara Financial Group go as follows:

  • 4-Week # shares bought: 3,511
  • 12-Week # shares bought: 3,511
  • 24-Week # shares bought: 8,585

The average volume for First Niagara Financial Group has been 4.1 million shares per day over the past 30 days. First Niagara Financial Group has a market cap of $2.8 billion and is part of the financial sector and banking industry. Shares are down 26.46% year-to-date as of the close of trading on Thursday.

First Niagara Financial Group, Inc. operates as the bank holding company for First Niagara Bank, N.A. that provides retail and commercial banking, and other financial services to individuals, families, and businesses. The stock currently has a dividend yield of 4.11%. Currently, there is 1 analyst who rates First Niagara Financial Group a buy, 3 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FNFG - FREE

TheStreet Quant Ratings rates First Niagara Financial Group as a hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full First Niagara Financial Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Skids and Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Dow Skids and Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar